UniQure Huntington's gene therapy durability questioned; patient perspective highlights unmet need

STAT reports on waning efficacy of UniQure's experimental Huntington's gene therapy, a concern for investors but less so for patients facing a fatal disease. The durability data is preliminary and unconfirmed, but the development underscores the high stakes for both the company and the patient community.